Cost-effectiveness of New Surgical Treatments for Hemorrhoidal Disease: A Multicentre Randomized Controlled Trial Comparing Transanal Doppler-guided Hemorrhoidal Artery Ligation With Mucopexy and Circular Stapled Hemorrhoidopexy. Issue 5 (November 2016)

• Record Type: Journal Article
• Authors: Lehur, Paul A.; Didnée, Anne S.; Faucheron, Jean-Luc; Meurette, Guillaume; Zerbib, Philippe; Siproudhis, Laurent; Vinson-Bonnet, Béatrice; Dubois, Anne; Casa, Christine; Hardouin, Jean-Benoit; Durand-Zaleski, Isabelle
• Is Part Of: Annals of surgery. Volume 264:Issue 5(2016:Nov.)
• Publication Date: 2016-11
• Subjects: circular stapled hemorrhoidopexy -- cost-effectiveness -- Doppler-guided artery ligation -- hemorrhoidal disease -- morbidity -- multicenter randomized trial -- outcome -- patient satisfaction -- risk assessment -- surgical treatment; Surgery -- Periodicals; 617.005
• DOI: 10.1097/SLA.0000000000001770
• Languages: English
• ISSNs: 0003-4932

Abstract

Abstract : Objective: To compare Doppler-guided hemorrhoidal artery ligation (DGHAL) with circular stapled hemorrhoidopexy (SH) in the treatment of grade II/III hemorrhoidal disease (HD). Background: DGHAL is a treatment option for symptomatic HD; existing studies report limited risk and satisfactory outcomes. DGHAL has never before been compared with SH in a large-scale multi-institutional randomized clinical trial. Methods: Three hundred ninety-three grade II/III HD patients recruited in 22 centers from 2010 to 2013 were randomized to DGHAL (n = 197) or SH (n = 196). The primary endpoint was operative-related morbidity at 3 months (D.90) based on the Clavien-Dindo surgical complications grading. Total cost, cost-effectiveness, and clinical outcome were assessed at 1 year. Results: At D.90, operative-related adverse events occurred after DGHAL and SH, respectively, in 47 (24%) and 50 (26%) patients ( P = 0.70). DGHAL resulted in longer mean operating time (44±16 vs 30±14 min; P < 0.001), less pain (postoperative and at 2 wks visual analogic scale: 2.2 vs 2.8; 1.3 vs 1.9; P = 0.03; P = 0.013) and shorter sick leave (12.3 vs 14.8 d; P = 0.045). At 1 year, DGHAL led to more residual grade III HD (15% vs 5%) and a higher reoperation rate (8% vs 4%). Patient satisfaction was >90% for both procedures. Total cost at 1 year was greater for DGHAL [[Euro sign]2806 ([Euro sign]2670; 2967) vs [Euro sign]2538 ([Euro sign]2386; 2737)]. The D.90, incremental cost-effectiveness ratio (ICER) was [Euro sign]7192 per averted complication. At 1 year DGHAL strategy was dominated. Conclusions: DGHAL and SH are viable options in grade II/III HD with no significant difference in operative-related risk. Although resulting in less postoperative pain and shorter sick leave, DGHAL was more expensive, took longer, and provided a possible inferior anatomical correction suggesting an increased risk of recurrence. Abstract : Supplemental Digital Content is available in the text